Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children
Completed · Phase 1 · Has a placebo group
Conditions studied: Respiratory Syncytial Virus Infections
In brief
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as drops in the nose. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 15 and 59 months who are seropositive to RSV.
Key facts
- Study ID
- NCT04444284
- Run by
- Meissa Vaccines, Inc.
- People needed
- 34
- Starts
- 2020-06-09
- Expected to finish
- 2021-05-07
- Last updated by the study team
- 2021-06-29
Who can join
Age: 1 and older, up to 5. Sex: any. Healthy volunteers: accepted.
Where it is running
- Meridian Clinical Research — Norfolk, Nebraska, United States
- Meridian Clinical Research — Omaha, Nebraska, United States
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.